Country
Clinical Trials in Malta
Studies with at least one site in Malta. Open a trial for its sites in Malta, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 3Diabetes Type 2, Heart Failure
RAPIDE: The Feasibility of a Hybrid Care Model
Rationale: During cross-border health emergencies, such as seen with the COVID-19 pandemic, health and care services are rapidly being overwhelmed by high numbers of patients requiring care, leading to stretches in the whole…
- Trial name
- NCT06735404
- Testing
- Hybrid care
- Where
- 4 sites in Italy, Malta and 2 more
- Volunteers
- 180 people
- Sponsor
- Radboud University Medical Center
Sepsis, Septic Shock
Molecular Subtype-Specific Mechanisms and Therapeutic Strategies in Sepsis
Sepsis is a complex syndrome that causes lethal organ dysfunction due to an abnormal host response to infection. No drug specifically targeting sepsis has been approved.
- Trial name
- MENDSEP (NCT06287684)
- Where
- Malta
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Mater Dei Hospital, Malta
Cardiac Disease, Coronary Artery Bypass
Distraction Therapy Using Virtual Reality in Cardiac Rehabilitation
The European Society of Cardiology has been putting forward the need for new adjuncts or models that optimise outcomes from CR programmes.
- Trial name
- NCT06898827
- Testing
- IVR using the Morpheus Programme, Cardiac Rehabilitation control group
- Where
- Malta
- Volunteers
- 20 people
- Sponsor
- University of Malta
Completed, with results posted
All –Breast Cancer
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using either tamoxifen or anastrozole may fight breast cancer by blocking the use of estrogen.
- Trial name
- IBIS-II DCIS (NCT00072462)
- Testing
- tamoxifen citrate, Anastrozole
- Where
- 97 sites in Australia, Austria and 12 more
- Volunteers
- 2,980 people
- Sponsor
- Queen Mary University of London
Breast Cancer
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
The purpose of this study is to investigate whether neratinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.
- Trial name
- ExteNET (NCT00878709)
- Testing
- neratinib
- Where
- 494 sites in United States, Australia and 38 more
- Volunteers
- 2,840 people
- Sponsor
- Puma Biotechnology, Inc.
Chronic Heart Failure (CHF)
A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
This low interventional study, whose unique intervention was to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary Care Physicians (PCPs) in Europe, assessed if…
- Trial name
- PREFER (NCT02807857)
- Testing
- Standard care
- Where
- 191 sites in Belgium, Croatia and 16 more
- Volunteers
- 1,415 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Cancer, Adenocarcinoma
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
- Trial name
- NCT00917384
- Testing
- ramucirumab, Best Supportive Care (BSC)
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for…
- Trial name
- NEFERTT (NCT00915018)
- Testing
- Neratinib, Trastuzumab, Paclitaxel
- Where
- 195 sites in United States, Australia and 33 more
- Volunteers
- 479 people
- Sponsor
- Puma Biotechnology, Inc.